Some people are the unique combination of visionary genius and thoughtful character. They connect the head and the heart.
Our guest for Rare Voices Episode 3 is one such person, Ken Greathouse. Ken is a veteran commercialization guru and a great friend. Ken has a decades-long point-of-view on developing innovative therapies with a proven track record in commercialization, sales and marketing for pharmaceuticals. When Ken sold Manchester Pharmaceuticals, he created the Greathouse Family Foundation with his wife, three sons, and daughter-in-law, in an effort to fund research for patients with orphan and rare disorders. The phrase, “That’s the way we have always done it,” does not apply to Ken. If you are ready to be provoked into a new way of thinking about how we could bring new therapies to market for people who need them the most, you won’t be disappointed with this conversation in Episode 3.
More About Ken
Ken Greathouse on LinkedIn
Ken Greathouse is a seasoned pharmaceutical executive with over 40 years of experience in sales, marketing, business development and commercial operations. He is the co-founder of several successful drug development companies, including Manchester Pharmaceuticals which was sold to Retrophin Inc. in 2014. He began his career with Lederle Laboratories where for over 18 years he held a number of sales and marketing positions of increasing responsibility. He joined Athena Neurosciences in 1993 and continued with Elan Pharmaceuticals after the acquisition of Athena. After a two-year tenure at Boron LePore and Associates as Vice President and General Manager of Contract Sales, he joined Questcor as Senior Vice President, Commercial Operations. Since leaving Questcor, Mr. Greathouse has co-founded and served as CEO of Argent Development Group LLC, Melbourne Laboratories LLC, Valcrest Pharmaceuticals LLC, and Hesperian BioPharma LLC, in addition to Manchester Pharmaceuticals LLC. He is a member of the board of directors for Zosano Pharma and the founder of the Greathouse Family Foundation.